Related Experiment Video

Updated: Feb 3, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.6K

Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC

Silvana Giacinti1, Giulia Poti2, Michela Roberto2

  • 1Belcolle Hospital ASL Viterbo, Viterbo, Italy silvanagiacinti@gmail.com.

Anticancer Research
|November 7, 2018
PubMed

Insights

Androgen deprivation therapy (ADT) is standard for advanced prostate cancer, but resistance develops, leading to castration-resistant prostate cancer (CRPC). Understanding resistance mechanisms is crucial for personalized treatment strategies to improve outcomes in CRPC patients.

Area of Science:

  • Oncology
  • Urology
  • Cancer Research

Background:

  • Androgen deprivation therapy (ADT) is the primary treatment for advanced prostate cancer.
  • A significant percentage of patients develop castration-resistant prostate cancer (CRPC) despite ADT.
  • Existing therapies for metastatic CRPC (mCRPC) often face primary or acquired resistance.

Purpose of the Study:

  • To review current evidence on major resistance mechanisms in prostate cancer treatment.
  • To explore new and future therapeutic approaches for CRPC.
  • To highlight the need for treatment personalization in CRPC.

Main Methods:

  • Literature review of current evidence.
  • Analysis of mechanisms of resistance to prostate cancer therapies.
  • Discussion of emerging therapeutic strategies.

Main Results:

  • Multiple factors contribute to CRPC treatment resistance.
  • Understanding these mechanisms is a key research area.
  • Personalized treatment is essential for improving effectiveness and reducing relapse in CRPC.

Conclusions:

  • Resistance to ADT and subsequent therapies is a major challenge in advanced prostate cancer.
  • Elucidating resistance mechanisms is critical for developing effective treatments.
  • Personalized therapeutic strategies are necessary to overcome resistance and improve patient survival in CRPC.
Keywords:
Prostate cancerandrogen deprivation therapydrug resistancemetastatic CRPCreview

More Related Videos

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

14.7K
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.9K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
833
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
519
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
714
Molecular Models02:00

Molecular Models

Physical models representing molecular architectures of chemical compounds play essential roles in understanding chemistry. The use of molecular models makes it easier to visualize the structures and shapes of atoms and molecules.
43.7K